Literature DB >> 25493017

CYLD deletion triggers nuclear factor-κB-signaling and increases cell death resistance in murine hepatocytes.

Toni Urbanik1, Bruno Christian Koehler1, Laura Wolpert1, Christin Elßner1, Anna-Lena Scherr1, Thomas Longerich1, Nicole Kautz1, Stefan Welte1, Nadine Hövelmeyer1, Dirk Jäger1, Ari Waisman1, Henning Schulze-Bergkamen1.   

Abstract

AIM: To analyze the role of CYLD for receptor-mediated cell death of murine hepatocytes in acute liver injury models.
METHODS: Hepatocyte cell death in CYLD knockout mice (CYLD(-/-) ) was analyzed by application of liver injury models for CD95- (Jo2) and tumor necrosis factor (TNF)-α- [D-GalN/lipopolysaccharide (LPS)] induced apoptosis. Liver injury was assessed by measurement of serum transaminases and histological analysis. Apoptosis induction was quantified by cleaved PARP staining and Western blotting of activated caspases. Nuclear factor (NF)-κB, ERK, Akt and jun amino-terminal kinases signaling were assessed. Primary Hepatocytes were isolated by two step-collagenase perfusion and treated with recombinant TNF-α and with the CD95-ligand Jo2. Cell viability was analyzed by MTT-assay.
RESULTS: Livers of CYLD(-/-) mice showed increased anti-apoptotic NF-κB signaling. In both applied liver injury models CYLD(-/-) mice showed a significantly reduced apoptosis sensitivity. After D-GalN/LPS treatment CYLD(-/-) mice exhibited significantly lower levels of alanine aminotransferase (ALT) (295 U/L vs 859 U/L, P < 0.05) and aspartate aminotransferase (AST) (560 U/L vs 1025 U/L, P < 0.01). After Jo injection CYLD(-/-) mice showed 2-fold lower ALT (50 U/L vs 110 U/L, P < 0.01) and lower AST (250 U/L vs 435 U/L, P < 0.01) serum-levels compared to WT mice. In addition, isolated CYLD(-/-) primary murine hepatocytes (PMH) were less sensitive towards death receptor-mediated apoptosis and showed increased levels of Bcl-2, XIAP, cIAP1/2, survivin and c-FLIP expression upon TNF- and CD95-receptor triggering, respectively. Inhibition of NF-κB activation by the inhibitor of NF-κB phosphorylation inhibitor BAY 11-7085 inhibited the expression of anti-apoptotic proteins and re-sensitized CYLD(-/-) PMH towards TNF- and CD95-receptor mediated cell death.
CONCLUSION: CYLD is a central regulator of apoptotic cell death in murine hepatocytes by controlling NF-κB dependent anti-apoptotic signaling.

Entities:  

Keywords:  Apoptosis; CD95; CYLD; Liver; Nuclear factor-κB; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2014        PMID: 25493017      PMCID: PMC4258573          DOI: 10.3748/wjg.v20.i45.17049

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  44 in total

1.  Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.

Authors:  Toni Urbanik; Regina Johanna Boger; Thomas Longerich; Katharina Becker; Karl Roland Ehrenberg; Nadine Hövelmeyer; Matthias Hahn; Marcus Schuchmann; Dirk Jäger; Ari Waisman; Marcus Alexander Wörns; Henning Schulze-Bergkamen
Journal:  J Hepatol       Date:  2012-06-21       Impact factor: 25.083

Review 2.  The proteasome in health and disease.

Authors:  Elzbieta Jankowska; Julia Stoj; Przemyslaw Karpowicz; Pawel A Osmulski; Maria Gaczynska
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 3.  Death receptors in liver biology and pathobiology.

Authors:  W A Faubion; G J Gores
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Negative regulation of JNK signaling by the tumor suppressor CYLD.

Authors:  William Reiley; Minying Zhang; Shao-Cong Sun
Journal:  J Biol Chem       Date:  2004-10-20       Impact factor: 5.157

Review 5.  Treat cancers by targeting survivin: just a dream or future reality?

Authors:  Mohane Selvaraj Coumar; Fang-Ying Tsai; Jagat Rakesh Kanwar; Sailu Sarvagalla; Chun Hei Antonio Cheung
Journal:  Cancer Treat Rev       Date:  2013-02-28       Impact factor: 12.111

6.  Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways.

Authors:  Edward M Conway; Saskia Pollefeyt; Marta Steiner-Mosonyi; Wei Luo; Astrid Devriese; Florea Lupu; Francoise Bono; Nathalie Leducq; Frederique Dol; Paul Schaeffer; Désiré Collen; Jean-Marc Herbert
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

Review 7.  Cellular and molecular mechanisms of liver injury.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 8.  NF-kappaB in liver diseases: a target for drug therapy.

Authors:  Pablo Muriel
Journal:  J Appl Toxicol       Date:  2009-03       Impact factor: 3.446

Review 9.  The CD95(APO-1/Fas) DISC and beyond.

Authors:  M E Peter; P H Krammer
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

10.  CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt.

Authors:  Jae Hyang Lim; Hirofumi Jono; Kensei Komatsu; Chang-Hoon Woo; Jiyun Lee; Masanori Miyata; Takashi Matsuno; Xiangbin Xu; Yuxian Huang; Wenhong Zhang; Soo Hyun Park; Yu-Il Kim; Yoo-Duk Choi; Huahao Shen; Kyung-Sun Heo; Haodong Xu; Patricia Bourne; Tomoaki Koga; Haidong Xu; Chen Yan; Binghe Wang; Lin-Feng Chen; Xin-Hua Feng; Jian-Dong Li
Journal:  Nat Commun       Date:  2012-04-10       Impact factor: 14.919

View more
  5 in total

1.  Hepatocyte Bcl-3 protects from death-receptor mediated apoptosis and subsequent acute liver failure.

Authors:  Nadine Gehrke; Marcus A Wörns; Amrit Mann; Nadine Hövelmeyer; Ari Waisman; Beate K Straub; Peter R Galle; Jörn M Schattenberg
Journal:  Cell Death Dis       Date:  2022-05-31       Impact factor: 9.685

2.  CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.

Authors:  Lei Yin; Shuai Liu; Chensheng Li; Sentai Ding; Dongbin Bi; Zhihong Niu; Liping Han; Wenjia Li; Dexuan Gao; Zheng Liu; Jiaju Lu
Journal:  Tumour Biol       Date:  2016-07-22

3.  The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells.

Authors:  Zhangding Wang; Qiang Wang; Guifang Xu; Na Meng; Xinli Huang; Zerun Jiang; Chen Chen; Yan Zhang; Junjie Chen; Aiping Li; Nan Li; Xiaoping Zou; Jianwei Zhou; Qingqing Ding; Shouyu Wang
Journal:  RNA Biol       Date:  2020-01-07       Impact factor: 4.652

4.  CYLD Deubiquitinase Negatively Regulates High Glucose-Induced NF-κB Inflammatory Signaling in Mesangial Cells.

Authors:  Yanhui Li; Wei Huang; Youhua Xu; Luping Zhou; Yaling Liang; Chenlin Gao; Yang Long; Yong Xu
Journal:  Biomed Res Int       Date:  2017-11-12       Impact factor: 3.411

5.  lncRNA-MEG3 Suppresses the Proliferation and Invasion of Melanoma by Regulating CYLD Expression Mediated by Sponging miR-499-5p.

Authors:  Jianwen Long; Xianming Pi
Journal:  Biomed Res Int       Date:  2018-04-02       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.